December 8, 2021 5:08pm
A “show me the money” session
Pre-open indication results: 12 HITs, 0 MISS
Who else is tracking a broad representative of cell and gene therapy equities – with facts supported by real numbers?
If I have learned one thing as a former research analyst, venture and public markets investor to a journalist; it is that your life and your bank account are largely tied to your questioning of price targets.
The Dow closed UP + 35.32 points (+0.10%); the S&P closed UP +14.65 points (+0.31%) while the Nasdaq closed UP +100.07 points (+0.64%)
Henry’omics:
Indexes were little changed as the market took a pause from this week’s rally, followed last week’s big omicron-induced sell-off.
Some of the comeback was validated by vaccine news Wednesday. Pfizer and BioNTech said three doses of their vaccine are effective at neutralizing the omicron variant, citing their own preliminary lab tests. They also said two doses may still protect against severe disease. <CNBC>
Economic data Docket: The number of workers who left their jobs due to dissatisfaction or better opportunities elsewhere fell in October by 4.7%, the Labor department said in its Job Openings and Labor Turnover Survey, also known as JOLTS, on Wednesday. The level of job openings accelerated 4.1% to just below its all-time high.
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …
- Wednesday opened positive at 16 ups/13 downs, 5 flats and 1 acquired, stayed positive at the mid-day at 26/6, 2 flats and 1 acquired, ending with a positive close of 24 up/7 downs, 3 flats and 1 acquired;
RegMed Investors’ (RMi) pre-open: “quick and hi-higher highs; say bye” … https://www.regmedinvestors.com/articles/12216
Pre-open indication results: 12 HITs: <Biostage (BSTG -$0.00); SELL into Strength: Intellia Therapeutics (NTLA -$0.67), CRISPR Therapeutics (CRSP +$1.02), Fate Therapeutics (FATE +$1.37), Ionis Pharmaceuticals (IONS +1.64), Editas Medicine (EDIT +$0.93), Vericel (VCEL +$0.94), Sage Therapeutics (SAGE +$0.52), Global Blood Therapeutics (GBT +$0.77), Ionis Pharmaceuticals (IONS +$1.64), Mesoblast (MESO -$0.05), Pluristem (PSTI +$0.00)> and 0 MISS
The Biostage (BSTG) Chronicles: Wednesday closed down -$0.34 with 160 shares traded after Tuesday closed down -$0.20 with 2,965 shares traded, Monday closed +$0.21 to $3.21 with 6,466 shares traded, Friday closed flat with 0 shares traded, Thursday closed up +$0.07 with 3,527 shares traded and last Wednesday closed up +$0.95 with 2,590 shares traded.
- What NO “pump and promote” today; does the pattern of months and months of trading volume express a time for the SEC to take a closer look?
Key Metric - volume
Sector volume LOW with 5 of the 24-upside having higher than the 3-month average volume with LOW volume of 3 of 7-downside having higher than the 3-month average volume;
Outstanding downside Volume:
- Solid Biosciences (SLDB -$0.08) with 6.557 m shares traded
Jumping with share pricing momentum (10 of 25):
- Ionis Pharmaceuticals (IONS +$1.64 after Tuesday’s +$3.07 and Monday’s +$1.11),
- Fate Therapeutics (FATE +$1.37 after Tuesday’s +$6.75 and Monday’s -$0.16),
- CRISPR Therapeutics (CRSP +$1.02 after Tuesday’s +$7.27 and Monday’s +$1.03),
- Vericel (VCEL +$0.94 after Tuesday’s +$2.24 and Monday’s +$1.81),
- Editas Medicine (EDIT +$0.93 after Tuesday’s +$2.90),
- Regenxbio (RGNX +$0.78),
- Global Blood Therapeutics (GBT +$0.77 after Tuesday’s +$1.45 and Monday’s +$0.71),
- uniQure NV (QURE +$0.55),
- Sage Therapeutics (SAGE +$0.52 after Tuesday’s +$2.11),
- Sangamo Therapeutics (SGMO +$0.25),
Hammered in today’s market (7 of 7):
- Ultragenyx (RARE -$3.43 after Tuesday’s +$5.55 and Monday’s +$2.88),
- Alnylam Pharmaceuticals (ALNY -$3.36 after Tuesday’s +$3.28 and Monday’s +$5.64),
- Intellia Therapeutics (NTLA -$0.67 after Tuesday’s +$16.34 and Monday’s -$0.27),
- AxoGen (AXGN -$0.13),
- Solid Biosciences (SLDB -$0.08),
- Brainstorm Cell Therapeutics (BCLI -$0.06 after Tuesday’s -$0.03),
- Mesoblast (MESO -$0.05)
Closing Flat:
- 3 – Biostage (BSTG), Pluristem (PSTI), ReNeuron (RENE.L) and -1 - Stemline Therapeutics (STML) – acquired
Stats:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Wednesday, the IBB closed up +1.13% and XBI closed up +1.43%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Wednesday was down -1.99 points or -9.09% at 19.90
December, the second month of Q4/21:
Wednesday closed positive with 24 incliners, 7 decliners, 3 flats and 1 acquired
Tuesday closed positive with 29 incliner, 4 decliners, 1 flat and 1 acquired
Monday (12/6) closed positive with 25 incliner, 9 decliners and 1 acquired
Friday closed negative with 1 incliner, 31 decliners, 2 flats and 1 acquired
Thursday closed positive with 26 incliners, 8 decliners and 1 acquired
Wednesday (12/1) closed negative with 4 incliners, 29 decliners, 1 flat and 1 acquired
The BOTTOM LINE: A good session, the oversold were further recognized and appreciated.
A session to “show me the money” … also, tread lightly, tax selling is upon us!
In any case, I have continued to write … don’t ramp exposure at the current levels.
There's also nothing wrong with standing pat after reducing exposure earlier in the month.
Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
